Patents by Inventor Jayson M. Rieger

Jayson M. Rieger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH
    Publication number: 20140213541
    Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).
    Type: Application
    Filed: October 7, 2013
    Publication date: July 31, 2014
    Applicant: ADENOSINE THERAPEUTICS, LLC
    Inventors: Onno Kranenburg, Jamila van der Bilt, Inne Borel Rinkes, Jayson M Rieger
  • Agonists of Aadenosine receptors for treating recurrent tumor growth
    Patent number: 8551972
    Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 8, 2013
    Assignee: Adenosine Therapeutics, LLC
    Inventors: Onno Kranenburg, Jarmila van der Bilt, Inne Borel Rinkes, Jayson M. Rieger
  • Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines
    Patent number: 8501941
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: August 6, 2013
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
  • METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS
    Publication number: 20130123208
    Abstract: The present invention includes a composition comprising an A2A agonist. The present invention also includes a method of treating or reducing the symptoms of a neuroinflammatory disease in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of an A2A agonist. In one embodiment, the A2A agonist is administered intrathecally to the patient. In another embodiment, the A2A agonist comprises ATL313.
    Type: Application
    Filed: May 12, 2011
    Publication date: May 16, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporation
    Inventors: Linda Watkins, Lisa C. Loram, Jayson M. Rieger
  • Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
    Patent number: 8420813
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates such as: wherein: R2 and R21 are defined in the description.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: April 16, 2013
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Jayson M Rieger, Robert Thompson
  • SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS
    Publication number: 20120309774
    Abstract: The present invention provides compounds of formulae Ia and Ib: wherein R1-5, Q, X, Y, Z, p, q, and r are as defined herein. The compounds are potent and selective antagonists of A2A adenosine receptors (ARs). The invention further includes pharmaceutical compositions containing these compounds and methods of using the same.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Inventors: Anthony BEAUGLEHOLE, Jayson M. RIEGER, Robert D. THOMPSON
  • Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as AR agonists
    Patent number: 8293720
    Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: October 23, 2012
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Robert D Thompson, Anthony Beauglehole, Frank Schmidtmann, Jayson M. Rieger
  • Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as AR agonists
    Patent number: 8263762
    Abstract: Provided herein are alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: September 11, 2012
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Anthony R. Beauglehole, Frank W. Schmidtmann, Jayson M. Rieger, Robert Thompson
  • METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES
    Publication number: 20120226040
    Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Applicant: DOGWOOD PHARMACEUTICALS, INC.
    Inventors: Guoquan WANG, Jayson M. RIEGER, Robert D. THOMPSON
  • Substituted 8-[6-amino-3-pyridyl]xanthines
    Patent number: 8258142
    Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines such as the following: and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 4, 2012
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Guoquan Wang, Robert D. Thompson, Jayson M. Rieger
  • Substituted aryl piperidinylalkynyladenosines as A2AR agonists
    Patent number: 8222228
    Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: July 17, 2012
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Jayson M. Rieger, Robert D. Thompson
  • Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
    Patent number: 8193200
    Abstract: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 5, 2012
    Assignees: University of Virginia Patent Foundation, Emory University
    Inventors: Shanthi V. Sitaraman, Joel M. Linden, Guoquan Wang, Robert Douglas Thompson, Jayson M. Rieger
  • Use of adenosine Amodulators to treat spinal cord injury
    Patent number: 8188063
    Abstract: The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one A2A receptor modulator to prevent injury to or enhance the healing of the injured cells.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: May 29, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Yuesheng Jason Li, Joel M. Linden, Jayson M. Rieger
  • Method to treat sickle cell disease
    Patent number: 8178509
    Abstract: The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: May 15, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Kori Wallace, Robert Alan Figler, Jayson M. Rieger
  • 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
    Patent number: 8158604
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 17, 2012
    Assignee: University of Virginia Patent Foundation
    Inventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • Pyrazolyl substituted xanthines
    Patent number: 8153628
    Abstract: The present invention provides compounds and pharmaceutical compositions that are substituted xanthines of formula I: or pharmaceutically acceptable salts thereof, wherein: Z is selected from the group consisting of oxazoyl, isoxazoyl, thiazolyl, and isothiazoyl; and Z1 is a 5-14 member substituted or unsubstituted heteroaryl ring; which are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: April 10, 2012
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Guoquan Wang, Jayson M Rieger, Robert D Thompson
  • SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS
    Publication number: 20120035192
    Abstract: The present invention provides compounds of formulae Ia and Ib: wherein R1-5, Q, X, Y, Z, p, q, and r are as defined herein. The compounds are potent and selective antagonists of A2A adenosine receptors (ARs). The invention further includes pharmaceutical compositions containing these compounds and methods of using the same.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 9, 2012
    Inventors: Anthony BEAUGLEHOLE, Jayson M. RIEGER, Robert D. THOMPSON
  • Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as AR agonists
    Patent number: 8058259
    Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: November 15, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Robert Douglas Thompson, Anthony Beauglehole, Frank W. Schmidtmann, Jayson M. Rieger
  • 2-propynyl adenosine analogs with modified 5?-ribose groups having A2A agonist activity
    Patent number: 7989431
    Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: August 2, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
  • Selective antagonists of Aadenosine receptors
    Patent number: 7985754
    Abstract: The present invention provides compounds of formulae Ia and Ib: wherein R1-5, Q, X, Y, Z, p, q, and r are as defined herein. The compounds are potent and selective antagonists of A2A adenosine receptors (ARs). The invention further includes pharmaceutical compositions containing these compounds and methods of using the same.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 26, 2011
    Assignee: Trovis Pharmaceuticals, LLC
    Inventors: Anthony Beauglehole, Jayson M. Rieger, Robert D. Thompson